Yangtze River Pharmaceutical Group Jiangsu Haici Biological Pharmaceutical is an API manufacturer based in China. It holds 25 active US drug master files across a filed portfolio of 25 molecules. Its filings concentrate with NPRA (MY), AEMPS (ES) and MINSA (CR). Its GMP standing is certified by EMA.
| Site | FDA FEI |
|---|---|
| Taizhou, China | Not on file |
| China, China | 3009173840 |
| China, China | 3030810525 |
| Molecule | Regulators | Docs |
|---|---|---|
| Afatinib | US FDA | 1 |
| Aripiprazole | US FDA | 1 |
| Dexmedetomidine | US FDA | 1 |
| Dexrazoxane | US FDA | 1 |
| Diquafosol | US FDA | 1 |
| Doxofylline | US FDA | 1 |
| Edaravone | US FDA | 1 |
| Empagliflozin | US FDA | 1 |
| Esomeprazole | US FDA | 1 |
| Gemcitabine | US FDA | 1 |
| Glimepiride | US FDA | 1 |
| Lenalidomide | US FDA | 1 |
| Lenvatinib | US FDA | 1 |
| Levosimendan | US FDA | 1 |
| Linagliptin | US FDA | 1 |
| Milrinone | US FDA | 1 |
| Parecoxib | US FDA | 1 |
| Pramipexole | US FDA | 1 |
| Propofol | US FDA | 1 |
| Regorafenib | US FDA | 1 |
| Sitafloxacin | US FDA | 1 |
| Sugammadex | US FDA | 1 |
| Tamoxifen | US FDA | 1 |
| Tedizolid | US FDA | 1 |
| Tofacitinib | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| NPRA (MY) | 10 | None |
| AEMPS (ES) | 3 | None |
| MINSA (CR) | 2 | None |
| ARCSA (EC) | 1 | None |
| EMA | None | 1 |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Yangtze River Pharmaceutical Group Jiangsu Haici Biological comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.